Magnetic resonance imaging (MRI) and spectroscopy course
Course dates
Unfortunately, for reasons beyond our control, we have had to cancel the MR course for October 2025. We intend to run the course as normal in 2026 so please check back again soon for the new course dates.
Venue
The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, UK.
Overview
This course is organised by the Joint Department of Physics of The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London.
The course has been running at the current venue since 1998. It gives an introduction to methods and applications of biomedical magnetic resonance imaging (MRI) and spectroscopy, assuming no prior knowledge of the principles of magnetic resonance.
The course is intended to be useful both for NHS physicists who deal with MRI in a clinical setting, and for scientists (such as postdocs and PhD students new to the field) performing research in the field of in vivo NMR. It includes the opportunity to virtually observe measurements demonstrated on one of the Siemens 1.5T MR systems, installed at The Royal Marsden NHS Foundation Trust. A provisional lecture list is available below.
The course assumes some familiarity with general principles of physics, but no specific knowledge of magnetic resonance.
Group tutorials are included to give students the opportunity to discuss the material in small groups, and to perform simple exercises to reinforce and extend the teaching of the formal lectures.
The course begins at 9.30am on Monday 13 October 2025, and finishes late afternoon on Wednesday 15 October 2025. One-and-a-half-hour group demonstrations may be included as part of the course on the Monday or Tuesday evenings.
This is a CPD course approved by IPEM.
Provisional lecture list
- Basis of NMR
- Relaxation Parameters and Spin Echoes
- Magnetic Field Gradients, Slice Selection and Frequency Encoding
- Basic Imaging Sequences: Spin-echo and Gradient Echo
- 2D FT Imaging, k-space
- Hardware - RF Requirements and RF Coils
- Safety Considerations
- Hardware - Magnets, Gradients and Eddy Currents
- Image Contrast, Resolution and Factors Affecting Signal-to-Noise
- MRI in Practice
- MRI in Radiotherapy Planning
- K-space trajectories
- Quantitative imaging
- Acceleration of MR sequences
- Diffusion MRI
- Introduction to in vivo MR Spectroscopy
- MR Spectroscopy Acquisition and Analysis
- MRI for Clinical Drug Development
- Flow and MR Angiography
- Functional Imaging Methods
- Clinical examples of MRI
Most lectures will be 45 minutes in duration.
Provisional list of lecturers
- Dr M Blackledge – ICR and RMH, Sutton
- Dr G Charles-Edwards – Guy's and St Thomas Hospitals, London and ICR
- Dr K De Paepe – Cambridge
- Dr S Doran – ICR and RMH, Sutton
- Dr M Graves – Addenbrookes Hospital, Cambridge
- Dr E Kousi – ICR and RMH, Sutton
- Dr P Murphy – The Janssen Pharmaceutical Companies of Johnson & Johnson
- Dr M Orton - RMH and ICR, Sutton
- Dr GS Payne – ICR and RMH, Sutton
- Dr M Rata – ICR and RMH, Sutton
- Dr M Schmidt – ICR and RMH, Sutton
- Professor G Barker – Kings College, London
- Dr J Winfield – RMH and ICR, Sutton
Registration & Course fees
Downloadable Registration Form (PDF)
All current course registration fees are given on our registration form.
The cost includes lunches and light refreshments. Lecture notes and a certificate of attendance are provided.
You will be allocated a place on receipt of a completed registration form and a valid quoted payment reference/purchase order or completed bank transfer/online payment. We are unable to accept provisional bookings.
The number of participants is limited, so early booking is advised. Applications from outside the UK are welcome.
Closing date for registrations - TBC
Related documents
Contacts
Course Organiser: Dr Simon Doran
For registration details and any other queries contact:
Course Administrator: Mrs Melisa Porter
Related pages
Latest ICR News
Blood test could spare men with advanced prostate cancer from futile chemotherapy
New research has identified a way to predict resistance to a cancer drug commonly used to treat advanced prostate cancer.
ICR researchers to contribute to £13.7m brain tumour research consortium
The NIHR has announced a £13.7 million investment into research to develop new brain tumour treatments in the UK. The funding will establish the NIHR Brain Tumour Research Consortium – a national partnership uniting hospitals, universities, cancer centres and charities, along with patients. This is a coordinated UK-wide effort, which will involve the ICR's scientists, aims to transform brain cancer treatment.
New structural insights reveal molecular details of a key step in cell cycle control
In a major advance for molecular biology and cancer research, scientists have uncovered the molecular mechanisms that control a key step during the activation of cyclin-dependent kinases (CDKs) – the master regulators of cell division.
Mapping myeloma mutations: study reveals why some drugs fail and others still work
A new study has shown that small genetic changes in a key protein can determine whether myeloma cells resist or respond to treatment – findings that could help clinicians choose more effective therapies for patients with this type of blood cancer.